Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Share-based Compensation: 2017-2025

Historic Share-based Compensation for Denali Therapeutics (DNLI) over the last 9 years, with Sep 2025 value amounting to $25.1 million.

  • Denali Therapeutics' Share-based Compensation rose 1.11% to $25.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.8 million, marking a year-over-year decrease of 2.92%. This contributed to the annual value of $102.9 million for FY2024, which is 4.83% down from last year.
  • Denali Therapeutics' Share-based Compensation amounted to $25.1 million in Q3 2025, which was down 0.99% from $25.4 million recorded in Q2 2025.
  • Denali Therapeutics' Share-based Compensation's 5-year high stood at $28.1 million during Q1 2023, with a 5-year trough of $21.0 million in Q3 2021.
  • In the last 3 years, Denali Therapeutics' Share-based Compensation had a median value of $25.4 million in 2025 and averaged $26.1 million.
  • Per our database at Business Quant, Denali Therapeutics' Share-based Compensation skyrocketed by 94.97% in 2021 and then declined by 9.63% in 2025.
  • Denali Therapeutics' Share-based Compensation (Quarterly) stood at $22.1 million in 2021, then climbed by 14.05% to $25.2 million in 2022, then increased by 3.18% to $26.0 million in 2023, then dropped by 3.50% to $25.1 million in 2024, then grew by 1.11% to $25.1 million in 2025.
  • Its Share-based Compensation stands at $25.1 million for Q3 2025, versus $25.4 million for Q2 2025 and $25.2 million for Q1 2025.